Skip to Content
ETF Comparisons

ARKG vs. VIG

ARK Genomic Revolution ETF

ARKG
$--
vs

Vanguard Dividend Appreciation ETF

VIG
$--

Correlation

Compare with

Top 10 comparisons with ARKG:
Compare:
ARKG
Correlation
With:
VIG
Vanguard Dividend Appreciation ETF
SwitchGNOMGlobal X Funds - Global X Genomics & Biotechnology ETF0.92ARKKARK Investment Management LLC - ARK Innovation ETF0.91TARKInvestment Managers Series Trust II - AXS 2X Innovation ETF0.91VBKVanguard Group, Inc. - Vanguard Small Cap Growth ETF0.86KOMPSPDR Series Trust - SPDR S&P Kensho New Economies Composite ETF0.85XBISPDR Series Trust - SPDR Biotech ETF0.85LABUDirexion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares0.85ARKFARK ETF Trust - ARK Fintech Innovation ETF0.84IPORenaissance Capital Greenwich Funds - Renaissance IPO ETF0.84ARKWARK Investment Management LLC - ARK Next Generation Internet ETF0.84

Top 10 shared holdings

The top 10 holdings shared by ARKG and VIG:

There are no shared holdings.
Invest with ARKG
Learn more about VIG
ARKGARK Genomic Revolution ETF
VIGVanguard Dividend Appreciation ETF

What is ARKG?

The Fund is concentrated in any industry or group of industries in the health care sector, including, in particular, issuers having their principal business activities in the biotechnology industry. Other industries in the health care sector include medical laboratories and research, drug manufacturers and agricultural chemicals.

Snapshot
**

ARKG ARK Genomic Revolution ETF
VIG Vanguard Dividend Appreciation ETF
Inception date
Oct 31, 2014
Apr 21, 2006
Expense ratio
0.75%
0.06%
ARKG has a higher expense ratio than VIG by 0.69%. This can indicate that it’s more expensive to invest in ARKG than VIG.
Type
Global Equities
US Equities
ARKG targets investing in Global Equities, while VIG targets investing in US Equities.
Fund owner
ARK Funds
Vanguard
ARKG is managed by ARK Funds, while VIG is managed by Vanguard.
Volume (1m avg. daily)
$36,384,198
$157,665,108
Both ARKG and VIG are considered high-volume assets. They’re less likely to be affected by issues like slippage and failed orders on Composer than low-volume assets.
AUM
$1,743,388,571
$67,239,425,848
ARKG has more assets under management than VIG by $65,496,037,277. Higher AUM can be associated with better liquidity and lower slippage in trading.
Associated index
None
S&P U.S. Dividend Growers Index
ARKG is based off of the undefined, while VIG is based off of the S&P U.S. Dividend Growers Index
Inverse/Leveraged
No
No
ARKG and VIG use the same leverage ratio. Inverse and leveraged ETFs can be used to either take an opposite position or amplify returns of a given index.
Passive/Active
Active
Passive
ARKG uses a Active investing strategy, while VIG uses a Passive investing strategy.
Dividend
No
Yes
VIG may offer dividends, while ARKG does not. The frequency and yield of the dividend for VIG may vary.
Prospectus
View
View
Neither ARKG nor VIG require a K1.

Automated Strategies
Related toARKG

#GLOBE

Follow the Global Trend

Category

Momentum, Lever Up, Go Global, Diversification

Risk Rating

Moderate

Automated Strategies
Related toVIG

#RB

Rotating Bonds

Category

Getting Defensive, Diversification

Risk Rating

Moderate

Create your own algorithmic
trading strategy

News Related to ARKG

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

May 19, 2025 • by Akanksha Bakshi
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Read

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics

Apr 12, 2025 • by Rounak Jain
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics
Read

Cathie Wood's Ark Invest Loads Up On Robinhood, Nvidia-Backed CoreWeave: Offloads Spotify, Roku

Mar 29, 2025 • by Rounak Jain
Cathie Wood's Ark Invest Loads Up On Robinhood, Nvidia-Backed CoreWeave: Offloads Spotify, Roku
Read

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

Mar 22, 2025 • by Rounak Jain
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Read

Disclaimers

*

We show information directly obtained from our data provider, Xignite. Data shown here is provided by Xignite, an unaffiliated third party. Composer believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate.

**

We show information based on calculations performed by Composer using data from our provider. Information provided here is based on calculations performed by Composer using data sourced from Xignite, an unaffiliated third party. Composer believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.